BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34296648)

  • 41. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
    Bárdi E; Bobok I; V Oláh A; Kappelmayer J; Kiss C
    Pathol Oncol Res; 2007; 13(3):249-53. PubMed ID: 17922055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
    Berman E; McBride M
    Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
    Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of charge and lipophilicity of daunorubicin and idarubicin on their penetration of model biological membranes - Langmuir monolayer and electrochemical studies.
    Matyszewska D
    Biochim Biophys Acta Biomembr; 2020 Feb; 1862(2):183104. PubMed ID: 31672546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
    Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
    J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia.
    Bassan R; Lerede T; Rambaldi A; Barbui T
    Acta Haematol; 1996; 95(3-4):188-92. PubMed ID: 8677741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [NT-pro-BNP in the evaluation of daunorubicin-indued cardiotoxicity in acute childhood leukemia].
    Hu M; Jiang H; Xia M
    Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):621-3. PubMed ID: 21122325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
    Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
    Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].
    Zhang Y; Yao XM; Zhu SL; Suo SS; Mao LP; Wei JY; Yu WJ; Mai WY; Tong HY; Meng HT; Qian WB; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):682-7. PubMed ID: 27587250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
    Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B
    Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC; Mandelli F
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract]   [Full Text] [Related]  

  • 58. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
    Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F
    Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.
    O'Brien TA; Russell SJ; Vowels MR; Oswald CM; Tiedemann K; Shaw PJ; Lockwood L; Teague L; Rice M; Marshall GM;
    Blood; 2002 Oct; 100(8):2708-16. PubMed ID: 12351376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
    Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
    Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.